Vir Biotechnology (VIR) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.09B and a free-cash-flow yield of -23.4%. Over the most recent reported fiscal year, revenue grew 4.4%. Nama's AI scorecard rates it Sell, 3.1 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 3.1/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Leading · +125.0% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-79.0%
How far the last close sits under the highest price of the past five years.
Market cap
$2.09B
Trailing P/E
—
Price / book
2.1
Price / sales
6.8
FCF yield
-23.4%
Dividend yield
—
Gross margin
100.3%
Operating margin
-92.6%
Net margin
-83.2%
Revenue growth (YoY)
+4.4%
Revenue growth (3-yr annual)
-65.2%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
1.6
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
VIR earnings
Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.62).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
-$0.57
-$0.75
+24.0%
-$200,000
Q2 2026
Aug 5, 2026
$0.47
$0.90
-47.8%
$238.94M
Q1 2026
May 6, 2026
-$0.85
$0.48
-277.1%
-$41,000
Q4 2025
Feb 23, 2026
-$0.31
-$0.45
+31.1%
$63.76M
VIR analyst price target
Median target $20.50 from 8 analysts, ranging $15.00 – $30.00.
Nama's AI scorecard currently rates Vir Biotechnology Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does VIR report earnings?
Vir Biotechnology's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.62.
What is the VIR price target?
The median analyst price target from 8 analysts is $20.50, with a range of $15.00 – $30.00.
Is VIR Shariah compliant?
Nama's AAOIFI-style screen reads Vir Biotechnology as Not Shariah Compliant. At least one of the three ratios or the industry test failed.